Professional Documents
Culture Documents
Responses To Oxygenation Perfusion and Transport Problems AY 2023 2024
Responses To Oxygenation Perfusion and Transport Problems AY 2023 2024
RESPONSES TO OXYGENATION-
PERFUSION AND TRANSPORT
PROBLEMS
CARDIOLOGY NURSING
THE CARDIOVASCULAR SYSTEM
Heart rate
Normal range is 60-100 beats per minute
Tachycardia is greater than 100 bpm
Bradycardia is less than 60 bpm
Sympathetic system INCREASES HR
Parasympathetic system (Vagus) DECREASES HR
The stroke volume is affected by preload, contractility and afterload.
◦ Frank Starling’s Law states that the more the myocardial fibers are
stretched, the greater the force of contraction.
◦ Preload- blood volume in the ventricles at the end of diastole before the
next contraction
◦ Afterload -peripheral resistance against which the left ventricle must pump
The Cardiovascular System
Blood pressure
a measure of the pressure exerted by the blood in
the arteries during heart contraction and relaxation.
Cardiac output X peripheral resistance
Control is neural (central and peripheral) and
hormonal
Baroreceptors in the carotid and aorta
Hormones- ADH, aldosterone, epinephrine can
increase BP; ANF can decrease BP
The Cardiovascular System
Troponin I and T
Troponin I is usually utilized for MI
Elevates
within 3-4 hours, peaks in 4-24
hours and persists for 7 days to 3 weeks!
Normal value for Troponin I is less than
0.6 ng/mL
The Cardiovascular System
LABORATORY PROCEDURES
Troponin I and T
REMEMBER to AVOID IM
injections before
obtaining blood sample!
Early and late diagnosis
can be made!
The Cardiovascular System
LABORATORY PROCEDURES
SERUM LIPIDS
Lipid profile measures the serum
cholesterol, triglycerides and
lipoprotein levels
Cholesterol= 200 mg/dL
Triglycerides- 40- 150 mg/dL
The Cardiovascular System
LABORATORY PROCEDURES
SERUM LIPIDS
LDH- 130 mg/dL
HDL- 30-70- mg/dL
NPO post midnight
(usually 12 hours)
The Cardiovascular System
LABORATORY PROCEDURES
ELECTROCARDIOGRAM (ECG)
A non-invasive procedure
that evaluates the electrical
activity of the heart
Electrodes and wires are
attached to the patient
The Cardiovascular System
LABORATORY PROCEDURES
Holter Monitoring
A non-invasive test in which
the client wears a Holter
monitor and an ECG tracing
recorded continuously over
a period of 24 hours
The Cardiovascular System
LABORATORY PROCEDURES
Holter Monitoring
Instruct the client to
resume normal activities
and maintain a diary of
activities and any symptoms
that may develop
The Cardiovascular System
LABORATORY PROCEDURES
ECHOCARDIOGRAM
Non-invasive test that studies
the structural and functional
changes of the heart with the
use of ultrasound
No special preparation is
needed
The Cardiovascular System
LABORATORY PROCEDURES
Stress Test
A non-invasive test that studies
the heart during activity and
detects and evaluates CAD
Exercise test, pharmacologic
test and emotional test
The Cardiovascular System
LABORATORY PROCEDURES
Stress Test
CARDIAC catheterization
Used to diagnose CAD, assess
coronary artery patency and determine
extent of atherosclerosis
The Cardiovascular System
LABORATORY PROCEDURES
Pretest:
Ensure Consent, assess for
allergy to seafood and iodine,
NPO, document weight and
height, baseline VS, blood
tests and document the
peripheral pulses
The Cardiovascular System
LABORATORY PROCEDURES
Pretest:
Fast for 8-12 hours,
teachings,
medications to allay
anxiety
The Cardiovascular System
LABORATORY PROCEDURES
Intra-test:
inform patient of a fluttery
feeling as the catheter
passes through the heart;
inform the patient that a
feeling of warmth and
metallic taste may occur
when dye is administered
The Cardiovascular System
LABORATORY PROCEDURES
Post-test:
Monitor VS and cardiac rhythm
Monitor peripheral pulses, color and
warmth and sensation of the
extremity distal to insertion site
Maintain sandbag to the insertion site
if required to maintain pressure
Monitor for bleeding and hematoma
formation
The Cardiovascular System
LABORATORY PROCEDURES
Maintain strict bed rest for 6-12 hours
Client may turn from side to side but
bed should not be elevated more than
30 degrees and legs always straight
Encourage fluid intake to flush out the
dye
Immobilize the arm if the antecubital
vein is used
Monitor for dye allergy
The Cardiovascular System
LABORATORY PROCEDURES
CVP
The CVP is the pressure
within the SVC
Reflects the pressure
under which blood is
returned to the SVC and
right atrium
The Cardiovascular System
LABORATORY PROCEDURES
CVP
Normal CVP is 2 to 8 mmHg/ 6-12 cm
H2O
Elevated CVP indicates increase in
blood volume, excessive IVF or
heart/renal failure
Low CVP may indicated hypovolemia,
hemorrhage and severe vasodilatation
The Cardiovascular System
LABORATORY PROCEDURES
Measuring CVP
1. Position the client supine .(if not
tolerated with bed elevated at 45
degrees)
2. Position the zero point of the CVP
line at the level of the right atrium.
Usually this is at the MAL, 4th ICS
3. Instruct the client to be relaxed and
avoid coughing and straining.
CARDIAC ASSESSMENT
ASSESSMENT
1. Health History
Obtain description of present
illness and the chief complaint
SOB, Edema, etc.
Assess risk factors
ASSESSMENT:
Chest Pain
2. Physical examination
Vital signs- BP, PP, MAP
Inspection of the skin
Inspection of the thorax
Palpation of the PMI, pulses
Auscultation of the heart sounds
CARDIAC ASSESSMENT
3. Laboratory and diagnostic studies
CBC
cardiac catheterization
Lipid profile
arteriography
Cardiac enzymes and proteins
CXR
CVP
EEG
Holter monitoring
Exercise ECG
CARDIAC IMPLEMENTATION
Coronary Artery
Disease(CAD)
Acute Coronary
Syndrome(ACS)
Hypertension
Vascular Disorders
Coronary Artery Disease (CAD)
It is sometimes called
coronary heart disease or
ischemic heart disease.
RISK FACTORS
Most important MODIFIABLE
factors:
Smoking
Hypertension
Diabetes
Cholesterol abnormalities
CAD
Pathophysiology
Fatty streak formation in the
vascular intima → T-cells and
monocytes ingest lipids in the
area of deposition→
atheroma→ narrowing of the
arterial lumen → reduced
coronary blood flow →
myocardial ischemia
CAD
Pathophysiology
There is decreased perfusion of
myocardial tissue and inadequate
myocardial oxygen supply
If 50% of the left coronary arterial
lumen is reduced or 75% of the other
coronary artery, this becomes
significant
Potential for Thrombosis and embolism
CAD
Symptoms of chronic CAD include:
o Physical activity
o Education about healthy living, including healthy eating, taking medicine as
prescribed, and ways to help you quit smoking
o Counseling to find ways to relieve stress and improve mental health
2. Lifestyle changes, such as eating a healthier (lower sodium, lower fat) diet,
increasing physical activity (aim for 30 minutes of walking five days a week,
or find activities client enjoy), reaching a healthy weight, and quitting
smoking, limit alcohol intake.
3. Medicines to treat risk factors for CAD, such as high cholesterol, high blood
pressure, or an irregular heartbeat.
CAD
Management:
Smoking
High blood pressure
High blood cholesterol
Diabetes
Physical inactivity
Being overweight or obese
A family history of chest pain, heart disease or
stroke
Management:
Medications:
The initial treatment for all ACS includes aspirin (300
mg) and heparin bolus and intravenous (IV) heparin
infusion if there are no contraindications
Antiplatelet therapy with ticagrelor or clopidogrel.
Ticagrelor is not given to the patients receiving
thrombolysis.
Beta-blockers, statin, and ACE inhibitors should be
initiated in all ACS cases as quickly as possible unless
contraindications exist.
Management:
Supportive measures like pain control with morphine/
fentanyl and oxygen in case of hypoxia.
ASSESSMENT FINDINGS
1. Chest pain- ANGINA
The most characteristic symptom
PAIN is described as mild to severe
retrosternal pain, squeezing,
tightness or burning sensation
Radiates to the jaw and left arm
Angina Pectoris
ASSESSMENT FINDINGS
1. Chest pain- ANGINA
Precipitated by Exercise, Eating
heavy meals, Emotions like
excitement and anxiety and
Extremes of temperature
Relieved by REST and
Nitroglycerin
Angina Pectoris
ASSESSMENT FINDINGS
2. Diaphoresis
3. Nausea and vomiting
4. Cold clammy skin
5. Sense of apprehension and
doom
6. Dizziness and syncope
Angina Pectoris
LABORATORY FINDINGS
1. ECG may show normal tracing if
patient is pain-free. Ischemic changes
may show ST depression and T wave
inversion
2. Cardiac catheterization
Provides the MOST DEFINITIVE
source of diagnosis by showing the
presence of the atherosclerotic
lesions
Angina Pectoris
NURSING MANAGEMENT
1. Administer prescribed medications
Nitrates- to dilate the coronary
arteries
Aspirin- to prevent thrombus
formation
Beta-blockers- to reduce BP and HR
Calcium-channel blockers- to dilate
coronary artery and reduce vasospasm
2. Teach the patient management of anginal attacks
Advise patient to stop all activities
Put one nitroglycerin tablet under the tongue
Wait for 5 minutes
If not relieved, take another tablet and wait for 5
minutes
Another tablet can be taken (third tablet)
If unrelieved after THREE tablets→ seek medical
attention
Nitroglycerin Dose
Angina Pectoris (Acute Relief)
0.3-0.6 mg SL q5min up to 3 times; use at first sign of angina
Types of Hypertension
1. Primary or ESSENTIAL
Most common type
2. Secondary
Due to other conditions like
Pheochromocytoma,
renovascular hypertension,
Cushing’s, Conn’s , SIADH
HYPERTENSION
PATHOPHYSIOLOGY
Multi-factorial etiology
BP= CO (SV X HR) x TPR (total peripheral resistance)
Any increase in the above parameters will increase BP
1. Increased sympathetic activity
2. Increased absorption of Sodium, and water in the kidney
3. Increased activity of the RAAS
4. Increased vasoconstriction of the peripheral vessels
5. insulin resistance
HYPERTENSION
ASSESSMENT FINDINGS
1. Headache
2. Visual changes
3. chest pain
4. dizziness
5. N/V
HYPERTENSION
Risk factors for Cardiovascular Problems in Hypertensive patients
Major Risk factors
1. Smoking
2. Hyperlipidemia
3. DM
4. Age older than 60
5. Gender- Male and post menopausal W
6. Family History
HYPERTENSION
DIAGNOSTIC STUDIES
1. Health history and PE
2. Routine laboratory- urinalysis, ECG,
lipid profile, BUN, serum creatinine ,
FBS
3. Other lab- CXR, creatinine
clearance, 24-huour urine protein
HYPERTENSION
MEDICAL MANAGEMENT
1. Lifestyle
modification
2. Drug therapy
3. Diet therapy
HYPERTENSION
MEDICAL MANAGEMENT
Drug therapy
Diuretics
Beta blockers
Calcium channel blockers
ACE inhibitors
A2 Receptor blockers
Vasodilators
HYPERTENSION
NURSING INTERVENTIONS
1. Provide health teaching to
patient
Teach about the disease process
Elaborate on lifestyle changes
Assist in meal planning to lose
weight
HYPERTENSION
NURSING INTERVENTIONS
1. Provide health teaching to the
patient
Provide list of LOW fat , LOW
sodium diet of less than 2-3 grams
of Na/day
Limit alcohol intake to 30 ml/day
Regular aerobic exercise
Advise to completely Stop smoking
HYPERTENSION
Nursing Interventions
2. Provide information about anti-
hypertensive drugs
Instruct proper compliance and not
abrupt cessation of drugs even if pt
becomes asymptomatic/ improved
condition
Instruct to avoid over-the-counter drugs
that may interfere with the current
medication
HYPERTENSION
Nursing Intervention
3. Promote Home care management
Instruct regular monitoring of BP
Involve family members in care
Instruct regular follow-up
4. Manage hypertensive emergency
and urgency properly
Vascular Diseases
ANEURYSM
Dilation involving an
artery formed at a
weak point in the
vessel wall
ANEURYSM
Fusiform=
when the entire
segment becomes dilated
ANEURYSM
RISK FACTORS
1. Atherosclerosis
2. Infection= syphilis
3. Connective tissue disorder
4. Genetic disorder= Marfan’s
Syndrome
ANEURYSM
PATHOPHYSIOLOGY
Damage to the intima and media→
weakness→ outpouching
ASSESSMENT
1. Asymptomatic
2. Pulsatile sensation on the abdomen
3. Palpable bruit
ANEURYSM
LABORATORY:
• CT scan
• Ultrasound
• X-ray
• Aortography
ANEURYSM
Collaborative Management:
• Anti-hypertensives
• Synthetic graft
ANEURYSM
Nursing Management:
• Administer medications
• Emphasize the need to avoid
increased abdominal pressure
• No deep abdominal palpation
• Remind patient the need for serial
ultrasound to detect diameter
changes
PERIPHERAL ARTERIAL
OCCLUSIVE DISEASE
Refers to arterial insufficiency
of the extremities usually
secondary to peripheral
atherosclerosis.
Usually found in males age 50
and above
The legs are most often
affected
PERIPHERAL ARTERIAL
OCCLUSIVE DISEASE
Risk factors for Peripheral
Arterial occlusive disease
Non-Modifiable
1. Age
2. gender
3. family predisposition
PERIPHERAL ARTERIAL
OCCLUSIVE DISEASE
Risk factors for Peripheral Arterial
occlusive disease
Modifiable
1. Smoking
2. HPN
3. Obesity
4. Sedentary lifestyle
5. DM
6. Stress
PERIPHERAL ARTERIAL OCCLUSIVE
DISEASE
ASSESSMENT FINDINGS
1. INTERMITTENT CLAUDICATION-
the hallmark of PAOD
This is PAIN described as aching,
cramping or fatiguing discomfort
consistently reproduced with the
same degree of exercise or
activity
PERIPHERAL ARTERIAL
OCCLUSIVE DISEASE
ASSESSMENT FINDINGS
1. INTERMITTENT CLAUDICATION-
the hallmark of PAOD
This pain is RELIEVED by REST
This commonly affects the
muscle group below the arterial
occlusion
PERIPHERAL ARTERIAL
OCCLUSIVE DISEASE
Assessment Findings
2. Progressive pain on the
extremity as the disease
advances
3. Sensation of cold and
numbness of the
extremities
PERIPHERAL ARTERIAL
OCCLUSIVE DISEASE
Assessment Findings
4. Skin is pale when
elevated and
cyanotic/ruddy when placed
on a dependent position
5. Muscle atrophy, leg
ulceration and gangrene
PERIPHERAL ARTERIAL
OCCLUSIVE DISEASE
Diagnostic Findings
1. Unequal pulses
between the extremities
2. Duplex
ultrasonography
3. Doppler flow studies
PAOD
Medical Management
1. Drug therapy
Pentoxyfylline (Trental) reduces blood
viscosity and improves supply of O2 blood
to muscles
Cilostazol (Pletaal) inhibits platelet
aggregation and increases vasodilatation
2. Surgery- Bypass graft and anastomoses
PERIPHERAL ARTERIAL
OCCLUSIVE DISEASE
Nursing Interventions
1. Maintain Circulation to the
extremity
Evaluate regularly peripheral
pulses, temperature, sensation,
motor function and capillary
refill time
Administer post-operative care to
patient who underwent surgery
PERIPHERAL ARTERIAL
OCCLUSIVE DISEASE
Nursing Interventions
2. Monitor and manage complications
Note for bleeding, hematoma,
decreased urine output
Elevate the legs to diminish edema
Encourage exercise of the extremity
while on bed
Teach patient to avoid leg-crossing
PERIPHERAL ARTERIAL
OCCLUSIVE DISEASE
Nursing Interventions
3. Promote Home
management
Encourage lifestyle changes
Instruct to AVOID smoking
Instruct to avoid leg
crossing
Care of Clients with
Oxygenation-Transport
Problems
Source:https://www.youtube.com/watch?v=5aOgQD1DjAI
Care of Clients with Oxygenation-
Transport Problems
Anemia
Nutritional anemia
Hemolytic anemia
Aplastic anemia
Sickle cell anemia
ANEMIA
A condition in which
the hemoglobin
concentration is lower
than normal
ANEMIA
IronDeficiency Anemia
Pathophysiology
The oxygen carrying
capacity of hemoglobin is
reduced→ tissue hypoxia
Hypoproliferative Anemia
Nursing Management
2. Administer iron
Oral preparations tablets- Fe
fumarate, sulfate and gluconate
Advise to take iron ONE hour before
meals
Take it with vitamin C
Continue taking it for several months
Hypoproliferative Anemia
Nursing Management
2. Administer iron
Oral preparations- liquid
It stains teeth
Drink it with a straw
Stool may turn blackish- dark in
color
Advise to eat high-fiber diet to
counteract constipation
Hypoproliferative Anemia
Nursing Management
2. Administer iron
IM preparation
Administer DEEP IM using the Z-track
method
Avoid vigorous rubbing
Can cause local pain and staining
APLASTIC ANEMIA
A condition
characterized by
decreased number of
RBC as well as WBC and
platelets
APLASTIC ANEMIA
CAUSATIVE FACTORS
1. Environmental toxins-
pesticides, benzene
2. Certain drugs-
Chemotherapeutic agents,
chloramphenicol, phenothiazines,
Sulfonamides
3. Heavy metals
4. Radiation
APLASTIC ANEMIA
Pathophysiology
Toxins cause a direct bone marrow
depression→ acellular bone
marrow→ decreased production of
blood elements
APLASTIC ANEMIA
ASSESSMENT FINDINGS
1. fatigue
2. pallor
3. dyspnea
4. bruising
5. splenomegaly
6. retinal hemorrhages
APLASTIC ANEMIA
LABORATORY FINDINGS
1. CBC- decreased blood cell
numbers
2. Bone marrow aspiration
confirms the anemia-
hypoplastic or acellular
marrow replaced by fats
APLASTIC ANEMIA
Medical Management
1. Bone marrow
transplantation
2. Immunosupressant
drugs
3. Rarely, steroids
4. Blood transfusion
APLASTIC ANEMIA
Nursing management
1. Assess for signs of
bleeding and infection
2. Instruct to avoid
exposure to offending
agents
Megaloblastic Anemias
Anemias characterized by
abnormally large RBC
secondary to impaired DNA
synthesis due to deficiency of
Folic acid and/or vitamin B12
Megaloblastic Anemias
Pernicious Anemia
Due to the absence of intrinsic factor
secreted by the parietal cells
Intrinsic factor binds with Vit. B12 to
promote absorption
Megaloblastic Anemias
Assessment findings
1. weakness
2. fatigue
3. listless
4. neurologic manifestations are
present only in Vit. B12 deficiency
Megaloblastic Anemias
Assessment findings
Pernicious Anemia
Beefy, red, swollen tongue
Mild diarrhea
Extreme pallor
Paresthesias in the extremities
Megaloblastic Anemias
Laboratory findings
1. Peripheral blood smear- shows giant
RBCs, WBCs with giant hypersegmented
nuclei
2. Very high MCV
3. Schilling’s test
4. Intrinsic factor antibody test
Megaloblastic Anemias
Medical Management
1. Vitamin supplementation
Folic acid 1 mg daily
2. Diet supplementation
Vegetarians should have vitamin intake
3.
Lifetime monthly injection of IM Vit
B12
Megaloblastic Anemias
Nursing Management
1. Monitor patient
2. Provide assistance in ambulation
3. Oral care for tongue sore
4. Explain the need for lifetime IM
injection of vit B12
Hemolytic Anemia: Sickle Cell
Causative factor
Genetic inheritance of the
sickle gene- HbS gene
Hemolytic Anemia: Sickle Cell
Pathophysiology
Decreased O2, Cold,
Vasoconstriction can
precipitate sickling
process
Hemolytic Anemia: Sickle Cell
Pathophysiology
Factors→ cause defective
hemoglobin to acquire a
rigid, crystal-like C-shaped
configuration→ Sickled
RBCs will adhere to
endothelium→ pile up and
plug the vessels→ ischemia
results→ pain, swelling and
fever
Hemolytic Anemia: Sickle Cell
Assessment Findings
1. jaundice
2. enlarged skull and
facial bones
3. tachycardia, murmurs
and cardiomegaly
Hemolytic Anemia: Sickle Cell
Assessment Findings
Primary sites of
thrombotic occlusion:
spleen, lungs and CNS
Chest pain, dyspnea
Hemolytic Anemia: Sickle Cell
Assessment Findings
1. Sickle cell crises
Results from tissue hypoxia and
necrosis
2. Acute chest syndrome
Manifested by a rapidly falling
hemoglobin level, tachycardia,
fever and chest infiltrates in the
CXR
Hemolytic Anemia: Sickle Cell
Medical Management
1. Bone marrow
transplant
2. Hydroxyurea
Increases the HbF
3. Long term RBC
transfusion
Hemolytic Anemia: Sickle Cell
Nursing Management
1. manage the pain
Support and elevate
acutely inflamed joint
Relaxation techniques
analgesics
Hemolytic Anemia: Sickle Cell
Nursing Management
2. Prevent and manage
infection
Monitor status of patient
Initiate prompt antibiotic
therapy
Hemolytic Anemia: Sickle Cell
Nursing Management
3. Promote coping skills
Provide accurate information
Allow patient to verbalize her
concerns about medication,
prognosis and future
pregnancy
Hemolytic Anemia: Sickle Cell
Nursing Management
4. Monitor and prevent
potential complications
Provide always adequate
hydration
Avoid cold, temperature that
may cause vasoconstriction
Hemolytic Anemia: Sickle Cell
Nursing Management
4. Monitor and prevent
potential complications
Leg ulcer
Aseptic technique
Hemolytic Anemia: Sickle Cell
Nursing Management
4. Monitor and prevent
potential complications
Priapism
Sudden painful erection
Instruct patient to empty
bladder, then take a warm bath
Polycythemia
POLYCYTHEMIA VERA
Primary Polycythemia
A proliferative disorder in
which the myeloid stem cells
become uncontrolled
Polycythemia
POLYCYTHEMIA VERA
Causative factor
unknown
Polycythemia
POLYCYTHEMIA VERA
Pathophysiology
The stem cells grow
uncontrollably
The bone marrow becomes
HYPERcellular and all the blood
cells are increased in number
Polycythemia
POLYCYTHEMIA VERA
Pathophysiology
The spleen resumes its function
of hematopoiesis and enlarges
Blood becomes thick and viscous
causing sluggish circulation
Polycythemia
POLYCYTHEMIA VERA
Pathophysiology
Overtime, the bone marrow
becomes fibrotic
Polycythemia
POLYCYTHEMIA VERA
Assessment findings
1. Skin is ruddy
2. Splenomegaly
3. headache
4. dizziness, blurred vision
5. Angina, dyspnea and
thrombophlebitis
Polycythemia
POLYCYTHEMIA VERA
Laboratory findings
1. CBC- shows elevated RBC
mass
2. Normal oxygen saturation
3 Elevated WBC and Platelets
Polycythemia
POLYCYTHEMIA VERA
Complications
1. Increased risk for
thrombophlebitis, CVA and MI
2. Bleeding due to
dysfunctional blood cells
Polycythemia
POLYCYTHEMIA VERA
Medical Management
1. To reduce the high blood cell
mass- PHLEBOTOMY
2. Allopurinol
3. Dipyridamole
4. Chemotherapy to suppress bone
marrow
Polycythemia
NursingManagement
1. Primary role of the nurse is
EDUCATOR
2. Regularly asses for the development
of complications
3. Assist in weekly phlebotomy
4. Advise to avoid alcohol and aspirin
5. Advise tepid sponge bath or cool
water to manage pruritus
Leukemia
ETIOLOGIC FACTORS
UNKNOWN
Probably exposure to radiation
Chemical agents
Infectious agents
Genetic
Leukemia
PATHOPHYSIOLOGY of ACUTE
Leukemia
Uncontrolled proliferation of
immature cells→ suppresses bone
marrow function→ severe anemia,
thrombocytopenia and
granulocytopenia
Leukemia
PATHOPHYSIOLOGY of CHRONIC
Leukemia
Uncontrolled proliferation of
DIFFERENTIATED cells→ slow
suppression of bone marrow
function→ milder symptoms
Leukemia
ASSESSMENT FINDINGS
ACUTE LEUKEMIA
Pallor
Fatigue
Dyspnea
Hemorrhages
Organomegaly
Headache
vomiting
Leukemia
ASSESSMENT FINDINGS
CHRONIC LEUKEMIA
Less severe symptoms
organomegaly
Leukemia
LABORATORY FINDINGS
Peripheral WBC count varies widely
Bone marrow aspiration biopsy reveals
a large percentage of immature cells-
BLASTS
Erythrocytes and platelets are
decreased
Leukemia
Collaborative Management
1. Chemotherapy
2. Bone marrow transplantation
Leukemia
Nursing Management
1. Manage AND prevent infection
Monitor temperature
Assess for signs of infection
Be alert if the neutrophil count drops
below 1,000 cells/mm3
Leukemia
Nursing Management
2. Maintain skin integrity